Myriad Genetics (MYGN) Q3 FY2026 earnings: revenue $203 million, down 1.5% on the year

Myriad Genetics Inc. (MYGN) reported revenue of $203 million for Q3 FY2026, the quarter ended 30 September 2026, down 1.5% on the same quarter a year earlier. Net income was -$44 million, and diluted earnings per share $-0.46. The figures are the company's own, from the 10-Q it filed with the SEC on 6 November 2026.

Revenue

$203 million

-1.5% on the year · +6.3% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

-19.7%

-11.3% a year earlier

Q4 FY2024Q3 FY2026

Net income

-$44 million

Q4 FY2024Q3 FY2026

Diluted EPS

-$0.46

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 narrowed, 2 new, 1 kept.

Revenue down 1% year-over-year: Revenue was $202.7 million, up 6% from the second quarter and down 1% year-over-year. Prior-year revenue was $205.7 million.
Revenue per test rose, volume fell: Average revenue per test rose 7% sequentially and 1% year-over-year on Cancer Care Continuum product mix and payer and revenue cycle work; total test volume fell 1% sequentially and 2% year-over-year.
Operating loss widened: Operating loss was $39.9 million, against $23.3 million a year earlier. Net loss was $43.9 million, or $0.46 per diluted share.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	203	191	206	+6.3%	-1.5%
Cost of revenue	65.0	63.7	61.9	+2.0%	+5.0%
Gross profit	138	127	144	+8.4%	-4.2%
Gross margin	67.9%	66.6%	69.9%
Research and development	26.5	25.0	28.2	+6.0%	-6.0%
Operating income	-39.9	-38.9	-23.3
Operating margin	-19.7%	-20.4%	-11.3%
Interest expense	4.1	4.1	3.8	0.0%	+7.9%
Pre-tax income	-43.6	-42.6	-26.2
Income tax	0.3	0.6	1.2	-50.0%	-75.0%
Net income	-43.9	-43.2	-27.4
Net margin	-21.7%	-22.7%	-13.3%
Diluted EPS	-$0.46	-$0.46	-$0.29

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-6.5	-8.3	21.1
Cash from investing	-2.1	-3.2	-6.2
Cash from financing	-0.3	2.2	56.2
Depreciation and amortisation	12.8	12.6	12.7	+1.6%	+0.8%
Share-based compensation	9.2	7.2	12.2	+27.8%	-24.6%
Diluted shares, weighted	96m	95m	93m	+0.9%	+2.8%
Shares outstanding at period end	96m	96m	93m	+0.1%	+2.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	269	304	373	-11.5%	-27.8%
Debt	121	121	120	+0.3%	+1.3%
Operating lease liabilities	80.5	82.5	84.9	-2.4%	-5.2%
Other liabilities	139	132	151	+5.2%	-8.2%
Total liabilities and equity	609	639	728	-4.6%	-16.3%
Fixed assets	105	109	111	-3.9%	-6.0%
Goodwill	47.1	47.1	51.6	0.0%	-8.7%
Intangible assets	132	139	163	-5.2%	-19.2%
Cash and equivalents	107	115	145	-7.0%	-26.3%
Receivables	106	110	118	-3.7%	-10.6%
Inventory	28.6	30.6	31.6	-6.5%	-9.5%
Other assets	84.4	88.6	107	-4.7%	-21.1%
Total assets	609	639	728	-4.6%	-16.3%

Questions

What was Myriad Genetics' revenue in Q3 FY2026?

Myriad Genetics (MYGN) reported revenue of $203 million for Q3 FY2026, the quarter ended 30 September 2026, down 1.5% on the same quarter a year earlier.

How much did Myriad Genetics earn in Q3 FY2026?

Net loss for Q3 FY2026 was $44 million, and the diluted loss per share $0.46.

When did Myriad Genetics report Q3 FY2026 results?

Myriad Genetics filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 6 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 * †	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	161	165	179	156	178	181	184	192	197	202	212	213	211	196	213	206	210	200	191	203
Cost of revenue	n/a	48.0	49.7	50.4	53.9	59.2	57.8	57.6	61.6	64.6	64.4	63.5	59.7	61.7	61.3	61.9	63.0	62.8	63.7	65.0
Gross profit	n/a	117	130	106	124	122	126	134	135	138	147	150	151	134	152	144	147	138	127	138
Gross margin	n/a	71%	72%	68%	70%	67%	69%	70%	69%	68%	70%	70%	72%	69%	71%	70%	70%	69%	67%	68%
R&D	20.5	21.2	20.3	20.5	23.4	22.5	21.2	24.0	21.0	24.9	27.1	28.5	32.9	27.5	25.6	28.2	25.5	27.1	25.0	26.5
SG&A	75.6	111	127	130	146	152	141	136	144	141	145	139	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating income	-43.1	-25.6	-17.8	-45.0	-52.2	-52.2	-114	-60.1	-31.4	-27.9	-36.5	-20.0	-39.1	-29.0	-329	-23.3	-5.7	-30.7	-38.9	-39.9
Operating margin	-27%	-16%	-10%	-29%	-29%	-29%	-62%	-31%	-16%	-14%	-17%	-9%	-19%	-15%	-154%	-11%	-3%	-15%	-20%	-20%
Interest expense	0.5	0.9	0.6	0.8	0.9	0.5	0.5	1.0	0.9	0.5	0.8	0.8	0.7	0.8	1.5	3.8	4.4	4.1	4.1	4.1
Pre-tax income	-43.5	-26.4	-17.9	-44.2	-52.1	-52.6	-116	-61.2	-32.3	-25.9	-37.2	-21.2	-39.2	-29.4	-331	-26.2	-8.9	-34.1	-42.6	-43.6
Net income	-7.6	-20.5	-14.1	-35.1	-42.3	-54.7	-116	-61.3	-31.2	-26.0	-36.7	-22.1	-42.5	-0.1	-330	-27.4	-7.9	-34.1	-43.2	-43.9
Net margin	-5%	-12%	-8%	-22%	-24%	-30%	-63%	-32%	-16%	-13%	-17%	-10%	-20%	-0%	-155%	-13%	-4%	-17%	-23%	-22%
Diluted EPS	-$0.07	-$0.26	-$0.18	-$0.43	-$0.52	-$0.67	-$1.42	-$0.75	-$0.36	-$0.29	-$0.41	-$0.24	-$0.47	$0.00	-$3.57	-$0.29	-$0.08	-$0.36	-$0.46	-$0.46
Operating cash flow	-9.9	-46.5	-50.3	-1.8	-7.7	-33.2	-0.9	-22.1	-54.7	-18.6	2.6	0.7	6.6	-16.3	-13.6	21.1	10.6	-15.7	-8.3	-6.5
Capital expenditure	3.4	6.3	6.7	17.7	14.6	23.5	18.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Free cash flow	-13.3	-52.8	-57.0	-19.5	-22.3	-56.7	-19.7	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares outstanding	80m	80m	81m	81m	81m	82m	82m	82m	90m	90m	91m	91m	91m	92m	93m	93m	94m	94m	96m	96m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 6 November 2026: the filing.